Senseonics Holdings (NASDAQ: SENS) saw its shares drop sharply by 5.26% during Monday's intraday session, despite the company reporting strong preliminary revenue growth for Q4 2025 and issuing optimistic guidance for 2026.
The medical technology company announced unaudited Q4 revenue of approximately $14.2 million, a 71% year-over-year increase, and full-year 2026 revenue guidance of $58-$62 million, representing growth of 65-76% over 2025. The decline in the stock price suggests investors may have been expecting even higher figures or opted to take profits after a recent rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.